CLU and Parkinson disease: Furthermore, levels of clusterin, apolipoprotein A1 (apoA1), and the complement C1r subcomponent were significantly lower in PD patients at Hoehn and Yar stages II and III (a scale for assessing the functional impairment caused by PD) compared to healthy controls [268].